Mount Sinai Health System has marked a groundbreaking advancement in the treatment of liver cancer by becoming the first healthcare institution globally to implement a newly FDA-cleared, minimally invasive radiation delivery system designed specifically for liver tumors. This innovative technology targets hepatic malignancies by administering therapeutic radiation directly into tumor vasculature through the bloodstream, significantly enhancing precision and minimizing collateral damage to surrounding healthy tissue.
The heart of this innovation lies in the TheraSphereâ„¢ Y-90 Any Day Dosing functionality, a component integrated within the TheraSphere 360â„¢ Management Platform. This cutting-edge system empowers clinicians to administer selective internal radiation therapy (SIRT) on multiple days throughout the week, overcoming previous limitations imposed by radioactive decay and fixed dosing schedules. By providing unprecedented scheduling flexibility, the platform streamlines patient care pathways and reduces delays in treatment initiation, which are critical factors in managing hepatocellular carcinoma (HCC), the dominant form of primary liver cancer worldwide.
Initial clinical implementation took place on March 30, 2026, under the expert guidance of Dr. Kirema Garcia-Reyes, an interventional radiologist and assistant professor affiliated with the Icahn School of Medicine at Mount Sinai. Dr. Garcia-Reyes collaborated closely with notable specialists such as Dr. Edward Kim and Dr. Robert Lookstein, both eminent figures in interventional oncology and image-guided therapies. These physicians collectively bring extensive expertise, blending innovative procedural techniques with multidimensional treatment approaches to improve patient outcomes in complex oncologic scenarios.
Hepatocellular carcinoma presents unique challenges due to its frequent association with underlying liver cirrhosis and multifaceted therapy regimens. The Mount Sinai Tisch Cancer Center serves as a multidisciplinary hub where the orchestration of surgical, radiologic, and systemic oncologic treatments necessitates intricate scheduling and coordination. The introduction of the Any Day Dosing protocol addresses this complexity by enabling more adaptable management of treatment timing, which is vital for patients potentially eligible for curative interventions such as liver transplantation.
TheraSphere Y-90 therapy involves the catheter-based delivery of yttrium-90 labeled microspheres into the hepatic artery, which preferentially supplies blood to tumors. This technique permits the direct deposition of beta-emitting radioactive particles within neoplastic lesions, achieving high local radiation doses while sparing normal hepatocytes. The microspheres become permanently lodged in the tumor microvasculature, exerting cytotoxic effects that impede tumor proliferation and may downstage disease to facilitate listing for liver transplantation or enhance candidacy for resection.
The TheraSphere 360 Management Platform is a sophisticated digital interface that integrates every aspect of the therapeutic workflow, from pre-procedure planning and dose calculation to product procurement and case documentation. This comprehensive solution supports multidisciplinary coordination and real-time decision-making. By circumventing the constraints of traditional dosing schedules — typically governed by radiopharmaceutical half-life decay dynamics — the Any Day Dosing feature affords physicians the ability to optimize treatment timing in alignment with individual patient needs and institutional resource availability.
Dr. Garcia-Reyes emphasized the patient-centered benefits of this advancement, highlighting the potential for shortened wait times and more patient-friendly scheduling during a treatment journey characterized by urgency and complexity. The ability to perform therapy on essentially any weekday diminishes logistical bottlenecks and facilitates tailored care plans that accommodate comorbidities and simultaneous treatments, which are common in the liver cancer patient population.
Mount Sinai’s early adoption of this technology reinforces its role at the forefront of oncology innovation. Through the integration of image-guided interventions and digital health solutions, the health system strives to elevate the standard of care, fostering improved tumor control rates, minimized adverse effects, and enhanced quality of life. The TheraSphere Any Day Dosing capability exemplifies the paradigm shift towards precision medicine, where customization of therapeutic delivery is paramount.
Moreover, this advancement holds promise beyond hepatocellular carcinoma, potentially impacting the management of metastatic liver disease, where selective internal radiation therapy has shown efficacy in controlling disease progression. With the enhanced operational flexibility provided by the new dosing system, institutions worldwide may adopt similar strategies, drastically broadening patient access to advanced locoregional therapies.
Technically, the success of the Any Day Dosing regimen depends on sophisticated dosimetric models that calculate radiation distribution within hepatic vasculature. The TheraSphere 360 platform integrates imaging modalities and artificial intelligence algorithms to accurately map tumor burden and optimize radiation delivery parameters. This computational precision mitigates overtreatment risks and fosters reproducibility across treatment centers.
Mount Sinai’s achievement symbolizes a major milestone not only in interventional oncology but also in the broader context of integrating digital health with therapeutic innovation. By dismantling temporal obstacles to care and advancing minimally invasive liver tumor treatment modalities, the health system enhances its mission of delivering equitable, high-quality, and timely cancer care.
As hepatic oncology continues to evolve, the synergy between novel medical devices, intelligent digital platforms, and multidisciplinary expertise at centers like Mount Sinai will play an increasingly critical role in transforming outcomes for patients confronted with formidable liver cancers worldwide.
Subject of Research: Liver cancer, minimally invasive radiotherapy, interventional oncology
Article Title: Mount Sinai Pioneers FDA-Cleared Any Day Dosing Radiotherapy System for Liver Cancer
News Publication Date: April 2, 2026
Web References: https://www.mountsinai.org
Keywords: liver cancer, hepatocellular carcinoma, TheraSphere Y-90, selective internal radiation therapy, minimally invasive treatment, interventional radiology, cancer therapy scheduling, digital health, radiation dosimetry, multidisciplinary cancer care
